Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
…, V Krishnan, R Liao, MLB Piruzeli… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …
properties. This study evaluates the efficacy and safety of baricitinib in combination …
[HTML][HTML] Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …
LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of …
Background Interventions to reduce mortality in critically ill patients with COVID-19 are a
crucial unmet medical need. Baricitinib (BARI) is an oral, selective Janus kinase (JAK)1/JAK2 …
crucial unmet medical need. Baricitinib (BARI) is an oral, selective Janus kinase (JAK)1/JAK2 …
[HTML][HTML] Baricitinib plus standard of care for hospitalized adults with COVID-19
…, CE Kartman, V Krishnan, R Liao, MLB Piruzeli… - MedRxiv, 2021 - medrxiv.org
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, improved outcomes
in a previous randomized controlled trial of hospitalized adults with COVID-19, in …
in a previous randomized controlled trial of hospitalized adults with COVID-19, in …
Efficacy and safety of baricitinib in patients with COVID-19 infection: results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER …
…, CE Kartman, V Krishnan, R Liao, MLB Piruzeli… - MedRxiv, 2021 - medrxiv.org
Background The efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor,
in addition to standard of care (SOC) in hospitalised adults with COVID-19 is unknown. …
in addition to standard of care (SOC) in hospitalised adults with COVID-19 is unknown. …
[HTML][HTML] Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis
…, H Elmaraghy, L DeLuca-Carter, MLB Piruzeli… - SKIN The Journal of …, 2023 - jofskin.org
BACKGROUND■ Lebrikizumab is a novel monoclonal antibody that binds with high affinity
and slow off-rate to IL-13, thereby blocking the downstream effects of IL-13 with high …
and slow off-rate to IL-13, thereby blocking the downstream effects of IL-13 with high …
494-Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
…, L DeLuca-Carter, MLB Piruzeli… - British Journal of …, 2024 - academic.oup.com
… Maria Lucia Buziqui Piruzeli , Maria Lucia Buziqui Piruzeli … Silverberg, Hany Elmaraghy,
Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline …
Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline …
[PDF][PDF] Emory University School of Medicine, Rollins School of Public Health, Emory Vaccine Center, and the Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA …
…, CE Kartman, V Krishnan, R Liao, MLB Piruzeli… - scholar.archive.org
Background: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, improved
outcomes in a previous randomized controlled trial of hospitalized adults with COVID-19, in …
outcomes in a previous randomized controlled trial of hospitalized adults with COVID-19, in …
Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 (preprint)
…, C Kartman, V Krishnan, R Liao, MLB Piruzeli… - 2021 - pesquisa.bvsalud.org
Background: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, improved
outcomes in a previous randomized controlled trial of hospitalized adults with COVID-19, in …
outcomes in a previous randomized controlled trial of hospitalized adults with COVID-19, in …
[HTML][HTML] Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema …
…, AR Atwater, MJ Rueda, J Zhong, MLB Piruzeli… - SKIN The Journal of …, 2023 - jofskin.org
… Maria Jose Rueda … Maria Lucia Buziqui Piruzeli … Emma Guttman-Yassky, Stephan
Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan …
Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan …